- Open Access
Assessment of Plasmodium falciparum resistance to ferroquine (SSR97193) in field isolates and in W2 strain under pressure
© Daher et al; licensee BioMed Central Ltd. 2006
Received: 27 October 2005
Accepted: 07 February 2006
Published: 07 February 2006
Ferroquine (FQ), or SSR97193, is a novel antimalarial drug currently in phase I clinical trials. FQ is a unique organometallic compound designed to overcome the chloroquine (CQ) resistance problem. FQ revealed to be equally active on CQ-sensitive and CQ-resistant Plasmodium falciparum laboratory strains and field isolates. FQ is also curative on rodent malaria parasites. As FQ will be tested in patients, the potential for resistance to this drug was evaluated.
The relationship between CQ-resistant transporter gene genotype and susceptibility to FQ were studied in 33 Cambodian P. falciparum field isolates previously studied for their in vitro response to CQ. In parallel, the ability of the CQ-resistant strain W2, to become resistant to FQ under drug pressure was assessed.
The IC50 values for FQ in field isolates were found to be unrelated to mutations occurring in the P. falciparum chloroquine resistance transporter (PfCRT) or to the level of expression of the corresponding mRNA. In vitro, under a drug pressure of 100 nM of FQ, transient survival was observed in only one of two experiments.
Field isolates studies and experimental drug pressure experiments showed that FQ overcomes CQ resistance, which reinforces the potential of this compound as a new antimalarial drug.
Drug resistance, particularly to CQ is an important limit to the control of P. falciparum, mainly in sub-Saharan Africa and South-east Asia. CQ is believed to act by concentrating in the parasite digestive vacuole and inhibiting the mechanism of detoxification of ferriprotoporphyrin IX that is produced during the digestion of haemoglobin, leading to parasite death. This detoxification takes place in the food vacuole and partly in the cytosol [1, 2]. It was shown that CQ-resistant parasites expelled much more rapidly the CQ from RBC than CQ-sensitive parasites, and many observations indicated that a P. falciparum transmembrane protein (PfCRT) was involved in this efflux [3–7]. Mutations of PfCRT have been described in all CQ-resistant P. falciparum isolates. Moreover, the reduction of PfCRT expression in vitro by genetic manipulation in P. falciparum resulted in an increase in CQ susceptibility . The genetic profile of CQ resistance in malaria parasites showed a particular mutation in PfCRT (K76T) that has been associated with CQ resistance in genetically modified P. falciparum strains and in field isolates [4–6].
Incidently, a previous study performed on Cambodian isolates with different levels of in vitro resistance to CQ failed to reveal an association between the K76T mutation in PfCRT protein and susceptibility to FQ, although a correlation was observed between in vitro responses to both drugs . Sequencing full length pfcrt cDNA of 42 isolates showed that other mutations than those already described can occur in the PfCRT protein. Six different PfCRT haplotypes were identified but the relation between these PfCRT haplotypes and susceptibility to FQ of isolates was not examined .
Ferroquine is currently in Phase 1 trials and its activity on P. falciparum uncomplicated malaria is planned to be evaluated in patients. For this reason, it was of interest to investigate whether a potential resistance to this drug may occur. For this purpose, a compilation was made of 155 results obtained from Cambodian isolates tested for their susceptibilities to CQ and FQ. Among them, pfcrt gene sequence and mRNA level expression were available for 33 isolates showing a large variation in FQ IC50. This led us, on one hand, to search a possible correlation between all mutations occurring in PfCRT protein and FQ susceptibility. On the another hand, we investigated wether the expression level of this gene may affect response to FQ. In parallel, the W2 strain, known to present a high capacity to acquire drug resistance, was submitted to FQ pressure at a sub-lethal dose [19–21].
Chloroquine diphosphate was purchased from Sigma. Ferroquine (SSR97193) base was obtained from Sanofi Aventis (France) and RPMI 1640 culture medium was purchased from Invitrogen. Human erythrocytes and plasma were obtained through the EFS (Etablissement Français du Sang, France).
The 3D7, HB3 and Dd2 strains of P. falciparum used as a control for sensitivity to CQ and FQ were cultured as previously described . For drug pressure experiments, a subclone of P. falciparum clone W2 was provided by Dr. B. Pradines (URBEP, Marseille, France). Parasites were grown in vitro in O+ human red blood cells in RPMI 1640 medium (Invitrogen) supplemented with 10% AB human serum (EFS), and 0.01 mg/ml gentamicin under an atmosphere 90% nitrogen/5% oxygen/5% carbon dioxide.
Complete data concerning CQ IC50, FQ IC50 and PfCRT protein sequences and pfcrt mRNA expression level were available for 33 of 155 patients previously recruited for in vivo trials of mefloquine-artesunate, by the Cambodian Ministry of Health. For these 33 patients a study concerning the relation between PfCRT mutations, expression of pfcrt mRNA and CQ resistance had already been performed [17, 18].
Antimalarial activity measurements
A microplate assay measuring [3H] hypoxanthine incorporation in parasite nucleic acids and derived from the method of Desjardins was used to test FQ antimalarial properties on laboratory strains . P. falciparum laboratory strains, were selected on the basis of their susceptibility to CQ (3D7 and HB3 were sensitive, Dd2 was moderately resistant and W2 was resistant). Culture conditions and test procedures were as previously described (0.5% haematocrit; 0.5% parasitaemia) [11, 12]. Ranges of drug concentrations used were 3.9–500 nM for CQ and 1.95–250 nM for FQ. IC50 were calculated from response curves by linear interpolation.
Nucleic acid extraction from W2 clone and PfCRT polymorphism
W2 clone RNA was extracted from freshly infected erythrocytes with an Rneasy extraction kit (Quiagen). The pfcrt gene was amplified by reverse transcription (RT)-PCR and then sequenced, as previously described .
Phylogenetic analysis of the PfCRT protein
In order to obtain a more accurate phylogeny of the PfCRT protein, a Bayesian phylogenetic analysis of PfCRT sequences was performed. For 3D7, Dd2 and HB3 clones, sequences were obtained from databanks (GenBank accession numbers: 3D7: CAD50842; Dd2: AAF26926; HB3: AAF60275). PfCRT sequences from field isolates were reported previously . In total, 37 full-length PfCRT amino acid sequences were aligned using the BioEdit v7.0.1 package . Alignment was facilitated by the fact that i) PfCRT protein sequences were extremely conserved (96–98% identity) and ii) none of these sequences exhibited any gaps or insertions, yielding 427 sites for analysis. The alignment used in this study is available upon request to the corresponding author. Phylogenetic analysis of this protein data set was carried out using software "MrBAYES", version 3_0b4 . Bayesian analysis was performed using the Jones-Taylor-Thornton (JTT) amino acid replacement model . Starting trees were random, four simultaneous Markov chains were run for 100,000 generations, burn-in values were set at 15,000 generations (based on empirical values of stabilizing likehoods), and trees were sampled every 100 generations. Bayesian posterior probabilities were calculated using a Markov chain Monte Carlo (MCMC) sampling approach implemented in MrBAYES 3_0b4 .
Exposure of parasites to FQ pressure
Susceptibilities of four P. falciparum strains to CQ and FQ. IC50 and IC90 are given ± the standard deviation. The number of experiments is in brackets
21.83 ± 4.5 (10)
45.74 ± 13.9 (10)
20.17 ± 6.0 (10)
28.61 ± 7.3 (10)
61.81 ± 28.7 (4)
166.75 ± 45.2 (4)
18.88 ± 4.3 (4)
28.40 ± 7.9 (4)
12.6 ± 5.9 (33)
35.9 ± 16 (30)
7.5 ± 3.3 (36)
13.1 ± 7.6 (36)
148.8 ± 60.3 (34)
> 500 (34)
13.2 ± 4.1 (38)
29 ± 11.5 (35)
Amino acid variations observed in PfCRT protein in 33 Cambodian isolates and laboratory strains within the phylogenic groups determined by Bayesian analysis. Composition of groups are as follows (laboratory clones and field isolates identified in : group 1: 608, 792, 3D7, HB3; group 2: 738; group 3: 602, 613, 634, 702, 734, 736, 770; group 4: 722, 742; group 5: Dd2, W2, 536, 572, 631, 637, 643, 647, 654, 665, 666, 671, 683, 685, 691, 693, 716, 717, 719, 739, 747, 749, 794.
IC50 CQ (nM)
IC50 FQ (nM)
In the first experiment, 0.86 × 1010 parasites were exposed to 100 nM of FQ. A rapid decrease in the parasite population was observed and Giemsa smears were negative after four days. No parasites were detected throughout the two months of monitoring. In the second experiment, the number of parasites cultivated was about 4 fold higher than in the first experiment (2.76 × 1010 parasites).
Estimation of parasite populations by flow cytometry
To count the low parasite populations detected on Giemsa stained smears, an intraerythrocytic parasite double staining method using hydroethidine (HE) and thiazole orange (TO) was used as previously described . Flow cytometric data acquisition and analysis were done on a FacsCalibur (Becton-Dickinson, San Jose, CA, USA). List mode data from 50,000 cells for control cultures and 106 cells for treated cultures were stored and processed with the CellQuest software.
Responses to ferroquine of laboratory strains and field isolates and relation with PfCRT polymorphism or pfcrt gene expression
Four laboratory strains of P. falciparum (for which PfCRT sequences was known) were tested for their susceptibility to CQ and FQ. As expected (Table 1), CQ IC50 measurements showed that HB3 and 3D7 were CQ-sensitive, that Dd2 was moderately resistant to CQ, while W2 was the most CQ-resistant. In addition, all strains presented lower IC50 to FQ (7.5 nM to 20.17 nM) than to CQ except for HB3 which responded equally to the two drugs.
Concerning the complete set of 155 isolates tested in Cambodia for FQ susceptibility, five isolates (3.22%) had an IC50 > 70 nM and two (1.3%) had an IC50 > 100 nM. Comparison of IC50 of field isolates showed a significant correlation (r2 = 0.3016) between CQ and FQ responses. Among this 155 isolates, data concerning pfcrt gene sequence and gene expression measurements done by Real Time PCR were available for 33 of them. In the subset selected for the present study, 51% of isolates were CQ sensitive (see legend of Table 2 of the present report and  for further details). The IC50 geometric mean (GM) observed were respectively 103.4 nM (range: 11.4 to 674 nM) for CQ and 31.5 nM (range: 7.50 to 120.2 nM) for FQ. Moreover, the five isolates displaying a FQ IC50 higher than 70 nM, and previously found in the total 155 isolates were present in this subset. This explains the higher correlation (r2 = 0.58) between CQ and FQ responses observed for these 33 isolates. It was previously shown that there was no correlation between the K76T mutation and susceptibility to FQ in a group of Cambodian isolates . On another hand, a relationship was demonstrated between the level of resistance to CQ and peculiar PfCRT haplotypes . In order to examine whether all mutations occurred on PfCRT protein could be responsible of higher FQ IC50, A Bayesian phylogenic analysis was performed on available data . The reconstructed phylogenic tree (data not shown) identified five groups numbered 1 to 5, each highly supported by a Bayesian posterior probability of 100%. Mutations in the PfCRT protein corresponding to these five groups are shown in Table 2 (group 1 represents the CQ sensitive laboratory strains or isolates and other groups the CQ resistant one). In this table, data concerning CQ and FQ IC50 are reported (calculation of geometric means for FQ IC50 were carried out for groups 1, 3 and 5). A large overlap observed between IC50 values, including the group 1, suggesting that none of PfCRT haplotypes analyzed could account for the variation in FQ sensitivity in the population studied. To study the possible role of PfCRT expression on FQ susceptibility, the relation between FQ IC50 and expression levels of pfcrt gene in field isolates using real time PCR (data not shown) was studied. The correlation observed (r2 = 0.0011) was not significant indicating that the expression level of pfcrt mRNA was not correlated with the FQ IC50. These results are in line with those related to previous studies concerning expression level of pfcrt mRNA and CQ response .
Experimental in vitro FQ pressure on W2 strain
Ferroquine (SSR97193), currently in Phase I, is soon to be tested in patients with uncomplicated P. falciparum malaria. Therefore, investigations into potential resistance to this drug candidate are necessary. Among all studies already devoted to the effects of FQ on field isolates, apparent lower responses to this drug were observed mainly in areas of multidrug resistance . The present study shows that the frequency of these decreased responses concerns about 3.22% of 155 Cambodian isolates if resistance threshold is fixed at 70 nM and about 1.3% if it is fixed at 100 nM. In the present study on P. falciparum field isolates or laboratory strains, it was possible to distinguish five polymorphic groups in PfCRT protein by a Bayesian phylogenic analysis. The examination of CQ and FQ IC50 in these five groups (Table 2) indicates that none of the different genotypes is directly associated with a decreased sensitivity to FQ. On the other hand, the level of expression of pfcrt mRNA is not correlated with the variations in FQ IC50. Insertion of the ferrocene moiety in the CQ lateral side chain results in modifications in the volume and shape of the molecule, as well as in its lipophilicity (logP = 5.1 versus 4.6 for CQ), its weak base properties and its electronic profile [10, 11]. It is possible that these changes confer a low affinity of FQ (in comparison with CQ) for PfCRT which appears to be extremely structure-specific [30, 31]. As a consequence, CQ resistant strains should be no more likely than others to develop FQ resistance. The drug pressure experiments done on W2 disproved this hypothesis. It has been impossible to recover a clone able to develop even in the absence of FQ in the culture medium. It seems that for surviving parasites, the cost of resistance to FQ may be too high in term of fitness [32–34]. In experimental conditions used, the frequency of parasites able to transiently survive to a sub-lethal dose of FQ is about 1 out of 1010. By comparison, experimental CQ pressure on the P. falciparum strain 106/1, which lacked only one mutation (K76T) on Pfcrt gene to acquire CQ resistance, led to a frequency of resistant parasites of about 10-9 . This mutation, which is due to a transversion of A to C and targeting the second base of the codon, is considered to be rare. Another study on the DHFR gene showed that the mutation rate of the gene at a given position occurred at less than 2.5 × 10-9 mutation/DHFR gene/replication . It was proposed that the resistance to CQ occurred four times in total over the whole history of this drug . Because more than one mutation has been necessary to provide a viable resistant genotype, it can be expected that a hypothetical resistance to FQ would develop at a low frequency.
Another known candidate for mediating potential resistance to FQ might be the P-glycoprotein homolog 1 (Pgh1) protein encoded by the pfmdr1 gene. All studies pointed to an absence of correlation between FQ and mefloquine responses in field isolates from Cambodia , Senegal  or Gabon . However, the question of pfmdr gene polymorphism or its copy number in isolates should be addressed to definitely rule out the possibility of a link between this marker and the response to FQ .
Analysis of the PlasmoDB database showed that other transporters were present in the parasite and might be involved in potential resistance to antimalarials [38–40]. It cannot be excluded that a resistance to FQ could develop in the future from a transporter encoded by one of these genes.
Recently, it has been suggested that the rapid development of drug resistance in the W2 strain could also be related to a defective DNA repair in this parasite . Using this strain and despite this ability, it was not possible to select a viable FQ-resistant line. This may be due to the number of mutations which may be necessary to promote the binding and the transport of FQ by a putative transporter.
The present results show that FQ susceptibility of 33 Cambodian P. falciparum field isolates was not related neither to phenotype of PfCRT protein nor to the level of gene expression. This indicates that CQ-resistant parasites as well as susceptible may be succumbing to FQ and confirms previous results observed on laboratory strains and field isolates. Pressure experiments done on W2 strain showed that the frequency of occurrence of FQ resistance is low in the experimental conditions used and that the cost of FQ resistance for the parasite is probably very expensive in term of fitness. This may be a limiting factor for spreading of potential FQ resistant parasites. In previous studies, it was shown that FQ security index, based on its cytotoxicity on L5178Y lymphoma cells, remained close to 700 whatever the CQ resistance level of P. falciparum used, when CQ security index falled from >1850 to >400 according to the CQ resistance of the strains . FQ, given subcutaneaously or orally cured equally mice infected by CQ-sensitive or CQ-resistant P. vinckei vinckei strains at a dose of 8.4 mg·kg-1·day-1 for four days with no adverse effects observed . On the basis of these promising results, together with its capacity to kill P. falciparum in vitro and to protect against rodent malaria, FQ is likely to provide a valuable new treatment to bypass the CQ resistance of P. falciparum.
We thank Dr Ray Pierce for his advices and for the revision of the manuscript. L. Mbeki was also thanked for proof reading. We thank Hadi Kalamou and Isabelle Ricard and P. Chim for their expert technical assistance. We also thank V. Durrand and A. Berry for their contribution in analysis of PfCRT sequences. We thank the National Malaria Center, Cambodian Ministry of Health, for its help in collecting field samples.
This work and Wassim Daher were supported by grants of Sanofi-Aventis and Fondation des Treilles.
- Egan TJ, Combrinck JM, Egan J, Hearne GR, Marques HM, Ntenteni S, Sewell BT, Smith PJ, Taylor D, van Schalkwyk DA, Walden JC: Fate of haem iron in the malaria parasite Plasmodium falciparum. Biochem J. 2002, 365: 343-347. 10.1042/BJ20020793.PubMed CentralView ArticlePubMedGoogle Scholar
- Ginsburg H, Ward SA, Bray PG: An integrated model of chloroquine action. Parasitol Today. 1999, 15: 357-360. 10.1016/S0169-4758(99)01502-1.View ArticlePubMedGoogle Scholar
- Sanchez CP, Stein W, Lanzer M: Trans stimulation provides evidence for a drug efflux carrier as the mechanism of chloroquine resistance in Plasmodium falciparum. Biochemistry. 2003, 42: 9383-9394. 10.1021/bi034269h.View ArticlePubMedGoogle Scholar
- Fidock DA, Nomura T, Talley AK, Cooper RA, Dzekunov SM, Ferdig MT, Ursos LM, Sidhu AB, Naude B, Deitsch KW, Su XZ, Wootton JC, Roepe PD, Wellems TE: Mutations in the P. falciparum digestive vacuole transmembrane protein PfCRT and evidence for their role in chloroquine resistance. Mol Cell. 2000, 6: 861-871. 10.1016/S1097-2765(05)00077-8.PubMed CentralView ArticlePubMedGoogle Scholar
- Djimde A, Doumbo OK, Cortese JF, Kayentao K, Doumbo S, Diourte Y, Dicko A, Su XZ, Nomura T, Fidock DA, Wellems TE, Plowe CV, Coulibaly D: A molecular marker for chloroquine-resistant falciparum malaria. N Engl J Med. 2001, 344: 257-263. 10.1056/NEJM200101253440403.View ArticlePubMedGoogle Scholar
- Howard EM, Zhang H, Roepe PD: A novel transporter, Pfcrt, confers antimalarial drug resistance. J Membr Biol. 2002, 190: 1-8. 10.1007/s00232-002-1019-3.View ArticlePubMedGoogle Scholar
- Wellems TE: Plasmodium chloroquine resistance and the search for a replacement antimalarial drug. Science. 2002, 298: 124-126. 10.1126/science.1078167.View ArticlePubMedGoogle Scholar
- Waller KL, Muhle RA, Ursos LM, Horrocks P, Verdier-Pinard D, Sidhu AB, Fujioka H, Roepe PD, Fidock DA: Chloroquine resistance modulated in vitro by expression levels of the Plasmodium falciparum chloroquine resistance transporter. J Biol Chem. 2003, 278: 33593-33601. 10.1074/jbc.M302215200.View ArticlePubMedGoogle Scholar
- Biot C, Glorian G, Maciejewski LA, Brocard JS: Synthesis and antimalarial activity in vitro and in vivo of a new ferrocene-chloroquine analogue. J Med Chem. 1997, 40: 3715-3718. 10.1021/jm970401y.View ArticlePubMedGoogle Scholar
- Biot C: Ferroquine: a new weapon in the fight against malaria. Current Medicinal Chemistry-Anti Infective Agents. 2004, 3: 135-147. 10.2174/1568012043354008.View ArticleGoogle Scholar
- Delhaës L, Abessolo H, Biot C, Deloron P, Karbwang J, Mortuaire M, Maciejewski LA, Camus D, Brocard J, Dive D: Ferrochloroquine, a ferrocenyl analogue of chloroquine, retains a potent activity against resistant Plasmodium falciparum in vitro and P. vinckei in vivo. Parasitol Res. 2001, 87: 239-244. 10.1007/s004360000317.View ArticlePubMedGoogle Scholar
- Delhaes L, Biot C, Berry L, Delcourt P, Maciejewski LA, Camus D, Brocard JS, Dive D: Synthesis of ferroquine enantiomers: first investigation of effects of metallocenic chirality upon antimalarial activity and cytotoxicity. Chembiochem. 2002, 3: 418-423. 10.1002/1439-7633(20020503)3:5<418::AID-CBIC418>3.0.CO;2-P.View ArticlePubMedGoogle Scholar
- Atteke C, Ndong JM, Aubouy A, Maciejewski L, Brocard J, Lebibi J, Deloron P: In vitro susceptibility to a new antimalarial organometallic analogue, ferroquine, of Plasmodium falciparum isolates from the Haut-Ogooue region of Gabon. J Antimicrob Chemother. 2003, 51: 1021-1024. 10.1093/jac/dkg161.View ArticlePubMedGoogle Scholar
- Domarle O, Blampain G, Agnaniet H, Nzadiyabi T, Lebibi J, Brocard J, Maciejewski L, Biot C, Georges AJ, Millet P: In vitro antimalarial activity of a new organometallic analog, ferrocene-chloroquine. Antimicrob Agents Chemother. 1998, 42: 540-544.PubMed CentralPubMedGoogle Scholar
- Pradines B, Fusai T, Daries W, Laloge V, Rogier C, Millet P, Panconi E, Kombila M, Parzy D: Ferrocene-chloroquine analogues as antimalarial agents: in vitro activity of ferrochloroquine against 103 Gabonese isolates of Plasmodium falciparum. J Antimicrob Chemother. 2001, 48: 179-184. 10.1093/jac/48.2.179.View ArticlePubMedGoogle Scholar
- Pradines B, Tall A, Rogier C, Spiegel A, Mosnier J, Marrama L, Fusai T, Millet P, Panconi E, Trape JF, Parzy D: In vitro activities of ferrochloroquine against 55 Senegalese isolates of Plasmodium falciparum in comparison with those of standard antimalarial drugs. Trop Med Int Health. 2002, 7: 265-270. 10.1046/j.1365-3156.2002.00848.x.View ArticlePubMedGoogle Scholar
- Chim P, Lim P, Sem R, Nhem S, Maciejewski L, Fandeur T: The in-vitro antimalarial activity of ferrochloroquine, measured against Cambodian isolates of Plasmodium falciparum. Ann Trop Med Parasitol. 2004, 98: 419-424. 10.1179/000349804225003361.View ArticlePubMedGoogle Scholar
- Durrand V, Berry A, Sem R, Glaziou P, Beaudou J, Fandeur T: Variations in the sequence and expression of the Plasmodium falciparum chloroquine resistance transporter (Pfcrt) and their relationship to chloroquine resistance in vitro. Mol Biochem Parasitol. 2004, 136: 273-285. 10.1016/j.molbiopara.2004.03.016.View ArticlePubMedGoogle Scholar
- Rathod PK, McErlean T, Lee PC: Variations in frequencies of drug resistance in Plasmodium falciparum. Proc Natl Acad Sci U S A. 1997, 94: 9389-9393. 10.1073/pnas.94.17.9389.PubMed CentralView ArticlePubMedGoogle Scholar
- Gassis S, Rathod PK: Frequency of drug resistance in Plasmodium falciparum: a nonsynergistic combination of 5-fluoroorotate and atovaquone suppresses in vitro resistance. Antimicrob Agents Chemother. 1996, 40: 914-919.PubMed CentralPubMedGoogle Scholar
- Cooper RA, Ferdig MT, Su XZ, Ursos LM, Mu J, Nomura T, Fujioka H, Fidock DA, Roepe PD, Wellems TE: Alternative mutations at position 76 of the vacuolar transmembrane protein PfCRT are associated with chloroquine resistance and unique stereospecific quinine and quinidine responses in Plasmodium falciparum. Mol Pharmacol. 2002, 61: 35-42. 10.1124/mol.61.1.35.View ArticlePubMedGoogle Scholar
- Trager W, Jensen JB: Human malaria parasites in continuous culture. Science. 1976, 193: 673-675.View ArticlePubMedGoogle Scholar
- Desjardins RE, Canfield CJ, Haynes JD, Chulay JD: Quantitative assessment of antimalarial activity in vitro by a semiautomated microdilution technique. Antimicrob Agents Chemother. 1979, 16: 710-718.PubMed CentralView ArticlePubMedGoogle Scholar
- Millet J, Alibert S, Torrentino-Madamet M, Rogier C, Santelli-Rouvier C, Bigot P, Mosnier J, Baret E, Barbe J, Parzy D, Pradines B: Polymorphism in Plasmodium falciparum drug transporter proteins and reversal of in vitro chloroquine resistance by a 9, 10-dihydroethanoanthracene derivative. Antimicrob Agents Chemother. 2004, 48: 4869-4872. 10.1128/AAC.48.12.4869-4872.2004.PubMed CentralView ArticlePubMedGoogle Scholar
- Huelsenbeck JP, Ronquist F: MRBAYES: Bayesian inference of phylogenetic trees. Bioinformatics. 2001, 17: 754-755. 10.1093/bioinformatics/17.8.754.View ArticlePubMedGoogle Scholar
- Jones DT, Taylor WR, Thornton JM: The rapid generation of mutation data matrices from protein sequences. Comput Appl Biosci. 1992, 8: 275-282.PubMedGoogle Scholar
- Green PJ: Reversible jump Markov chain Monte Carlo computation and Bayesian model determination. Biometrika. 1995, 82: 711-732.View ArticleGoogle Scholar
- Jouin H, Daher W, Khalife J, Ricard I, Puijalon OM, Capron M, Dive D: Double staining of Plasmodium falciparum nucleic acids with hydroethidine and thiazole orange for cell cycle stage analysis by flow cytometry. Cytometry A. 2004, 57: 34-38. 10.1002/cyto.a.10110.View ArticlePubMedGoogle Scholar
- Martin RE, Kirk K: The malaria parasite's chloroquine resistance transporter is a member of the drug/metabolite transporter superfamily. Mol Biol Evol. 2004, 21: 1938-1949. 10.1093/molbev/msh205.View ArticlePubMedGoogle Scholar
- Warhurst DC: Polymorphism in the Plasmodium falciparum chloroquine-resistance transporter protein links verapamil enhancement of chloroquine sensitivity with the clinical efficacy of amodiaquine. Malar J. 2003, 2: 31-43. 10.1186/1475-2875-2-31.PubMed CentralView ArticlePubMedGoogle Scholar
- Walliker D, Hunt P, Babiker H: Fitness of drug-resistant malaria parasites. Acta Trop. 2005, 94: 251-259.View ArticlePubMedGoogle Scholar
- Hastings IM, Donnelly MJ: The impact of antimalarial drug resistance mutations on parasite fitness, and its implications for the evolution of resistance. Drug Resist Updat. 2005, 8: 43-50. 10.1016/j.drup.2005.03.003.View ArticlePubMedGoogle Scholar
- Hayward R, Saliba KJ, Kirk K: pfmdr1 mutations associated with chloroquine resistance incur a fitness cost in Plasmodium falciparum. Mol Microbiol. 2005, 55: 1285-1295. 10.1111/j.1365-2958.2004.04470.x.View ArticlePubMedGoogle Scholar
- Paget-McNicol S, Saul A: Mutation rates in the dihydrofolate reductase gene of Plasmodium falciparum. Parasitology. 2001, 122: 497-505. 10.1017/S0031182001007739.View ArticlePubMedGoogle Scholar
- Anderson TJ, Roper C: The origins and spread of antimalarial drug resistance: lessons for policy makers. Acta Trop. 2005, 94: 269-280.View ArticlePubMedGoogle Scholar
- Price RN, Uhlemann AC, Brockman A, McGready R, Ashley E, Phaipun L, Patel R, Laing K, Looareesuwan S, White NJ, Nosten F, Krishna S: Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number. Lancet. 2004, 364: 438-447. 10.1016/S0140-6736(04)16767-6.PubMed CentralView ArticlePubMedGoogle Scholar
- Klokouzas A, Shahi S, Hladky SB, Barrand MA, van Veen HW: ABC transporters and drug resistance in parasitic protozoa. Int J Antimicrob Agents. 2003, 22: 301-317. 10.1016/S0924-8579(03)00210-3.View ArticlePubMedGoogle Scholar
- Mu J, Ferdig MT, Feng X, Joy DA, Duan J, Furuya T, Subramanian G, Aravind L, Cooper RA, Wootton JC, Xiong M, Su XZ: Multiple transporters associated with malaria parasite responses to chloroquine and quinine. Mol Microbiol. 2003, 49: 977-989. 10.1046/j.1365-2958.2003.03627.x.View ArticlePubMedGoogle Scholar
- Ferdig MT, Cooper RA, Mu J, Deng B, Joy DA, Su XZ, Wellems TE: Dissecting the loci of low-level quinine resistance in malaria parasites. Mol Microbiol. 2004, 52: 985-997. 10.1111/j.1365-2958.2004.04035.x.View ArticlePubMedGoogle Scholar
- Trotta RF, Brown ML, Terrell JC, Geyer JA: Defective DNA repair as a potential mechanism for the rapid development of drug resistance in Plasmodium falciparum. Biochemistry. 2004, 43: 4885-4891. 10.1021/bi0499258.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.